Global Antibiotic R&D Partnership (GARDP)
Franz Nimrod Aurelio, CPA, currently serves as a Tax Analyst II at Chevron, focusing on US tax compliance and reporting, including 1099 information reporting and withholding. Previously, Franz held senior analyst positions at Deutsche Bank, where responsibilities included quality assurance for US international private banking and UK risk and regulatory reporting, with significant contributions to financial reporting and oversight. Earlier career experience includes an assurance role at SGV & Co., where Franz excelled in audit engagements and mentoring new associates. Franz earned a Bachelor of Science degree in Accountancy from the University of Santo Tomas.
This person is not in any offices
Global Antibiotic R&D Partnership (GARDP)
The Global Antibiotic Research & Development Partnership (GARDP) is a not-for-profit organization that develops new antibiotic treatments for drug-resistant bacterial infections that pose the greatest threat to human health, and makes them accessible to the people who need them. It puts public health needs at the centre of antibiotic drug development to address both the immediate antimicrobial resistance (AMR) crisis and to ensure people continue to get access to essential antibiotics for generations to come. GARDP works through a global network including Brazil, India, Japan, and South Africa for antibiotic development and access. Its work is made possible by essential funding from donors and collaboration with over 100 R&D and access partners in over 20 countries. GARDP was created by the World Health Organization and the Drugs for Neglected Diseases initiative (DNDi) in 2016 and legally registered as the GARDP Foundation in Geneva, Switzerland in 2018. www.gardp.org